证券代码：600668 证券简称：尖峰集团 公告编号：临 2026-003 浙江尖峰集团股份有限公司 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本期业绩预告适用于实现盈利，且净利润与上年同期相比上升 50%以上 的情形。 2025 年 1 月 1 日至 2025 年 12 月 31 日。 浙江尖峰集团股份有限公司（以下简称"本公司"）预计 2025 年年度实 现归属于上市公司股东的净利润 46,000 万元左右，与上年同期相比，将增加 35,201.19 万元左右，同比增加 325.97%左右。 预计 2025 年年度实现归属于上市公司股东的扣除非经常性损益的净利 润-21,500 万元左右，与上年同期相比，将减少 31,161.77 万元左右，同比减少 322.53%左右。 一、本期业绩预告情况 （一）业绩预告期间 （二）业绩预告情况 1、经财务部门初步测算，预计 2025 年年度实现归属于上市公司股东的净利 润 46,000 万元左右，与上年同期相比，将增加 35,201 ...

格隆汇1月27日丨尖峰集团(600668.SH)公布，本公司预计2025年年度实现归属于上市公司股东的净利润 4.6亿元左右，与上年同期相比，将增加3.52亿元左右，同比增加325.97%左右。 预计2025年年度实现归属于上市公司股东的扣除非经常性损益的净利润-2.15亿元左右，与上年同期相 比，将减少3.12亿元左右，同比减少322.53%左右。 本期业绩变动的主要原因:1、2025年年度归属于上市公司股东的净利润大幅增加、扣除非经常性损益的 净利润大幅减少的主要原因是报告期公司权益法核算的联营企业天士力生物医药产业集团有限公司出售 了其所持的股权资产，使得其报告期的利润大幅增长，该部分出售资产所得的收益为非经常性收益。2. 报告期，公司持续开展节能降耗改造工作，严格控制产品成本，但水泥和熟料产品价格和销量同比均下 降。报告期，受药品集采、降费等政策及农药市场价格持续走低等因素的影响，公司的医药板块主要产 品的价格和销量同比均下降。3、报告期，经董事会批准，子公司浙江尖峰药业有限公司终止了注射用 去氧鬼臼毒素项目的临床试验及后续开发，根据《企业会计准则》等相关规定，基于会计谨慎性原则， 将该项目计入开发支 ...

每经AI快讯，1月27日，尖峰集团(600668.SH)公告称，预计2025年归属于上市公司股东的净利润为4.60 亿元左右，同比增加325.97%左右。业绩变动主要原因是联营企业天士力集团出售股权资产产生大额非 经常性收益。 ...

尖峰集团公告，预计2025年年度实现归属于上市公司股东的净利润4.6亿元左右，与上年同期相比，将 增加3.52亿元左右，同比增加325.97%左右。预计2025年年度实现归属于上市公司股东的扣除非经常性 损益的净利润-2.15亿元左右，与上年同期相比，将减少3.12亿元左右，同比减少322.53%左右。 ...

Group 1 - The cement sector experienced a decline of 0.92% on January 16, with Jinyu Group leading the drop [1] - The Shanghai Composite Index closed at 4101.91, down 0.26%, while the Shenzhen Component Index closed at 14281.08, down 0.18% [1] - Key stocks in the cement sector showed varied performance, with Xizang Tianlu rising by 3.02% to a closing price of 11.25, while Jinyu Group fell by 9.95% to 1.90 [1][2] Group 2 - The cement sector saw a net inflow of 126 million yuan from institutional investors, while retail investors experienced a net outflow of 161 million yuan [2] - The trading volume for Xizang Tianlu was 1.2037 million hands, with a transaction value of 1.37 billion yuan, indicating strong interest despite the overall sector decline [1][2] - The main capital inflow was concentrated in stocks like Xizang Tianlu and Guotong Shares, with net inflows of 207 million yuan and 16.56 million yuan respectively [3]

Core Viewpoint - Zhejiang Jianfeng Group Co., Ltd. announced that its subsidiary, Jianfeng Pharmaceutical, has voluntarily withdrawn the clinical trial application for the drug "C2235 and C2235 tablets" to the National Medical Products Administration, pending further research and will resubmit the application at a later date [2][3]. Group 1: Drug Registration and Withdrawal - Jianfeng Pharmaceutical received a termination notice for the drug registration application for "C2235 and C2235 tablets" from the National Medical Products Administration, indicating that the withdrawal was a proactive decision by the company [2]. - The withdrawal was due to the need for further improvement of the application materials during the registration process [2]. Group 2: Impact on Company Performance - The withdrawal of the clinical trial application for "C2235 and C2235 tablets" is not expected to have a significant impact on the company's current performance [3]. - The company acknowledges that the research and development of innovative drugs involve high technology and risks, with long and complex cycles from development to production, which are susceptible to unpredictable factors [3].

Group 1 - Siyuan Electric reported a total operating revenue of 21.205 billion yuan for 2025, a year-on-year increase of 37.18%, with a net profit attributable to shareholders of 3.163 billion yuan, up 54.35% year-on-year [1] - VisiOn expects a negative net profit for 2025, indicating a loss in operating performance [2] - Chongqing Steel anticipates a net loss of 2.5 billion to 2.8 billion yuan for 2025, which is an improvement from a net loss of 3.196 billion yuan in the previous year [3] - Lianfa Co. forecasts a net profit of 280 million to 320 million yuan for 2025, representing a year-on-year growth of 38.92% to 58.77% [4] Group 2 - CICC announced that the audit work related to the absorption merger with Dongxing Securities and Xinda Securities has not yet been completed [5] - Dalong Real Estate's subsidiary won a project bid worth 763 million yuan [6] - Zhongchuang Zhiling plans to issue convertible bonds to raise no more than 4.35 billion yuan for various projects [7] - Jintong Co. intends to acquire a 24% stake in Jinsha Molybdenum for 1.731 billion yuan [8] Group 3 - Nami Technology expects a net profit of 128 million to 145 million yuan for 2025, an increase of 54.51% to 75.03% year-on-year [9] - China State Construction reported a new contract total of 4.5458 trillion yuan for 2025, a 1% increase year-on-year [12] - China Metallurgical Group's new contract amount for 2025 is expected to decrease by 10.8% to 1.1136 trillion yuan [13] Group 4 - Beiding Co. reported a net profit of 111 million yuan for 2025, a year-on-year increase of 59.05% [14] - Southwest Securities expects a net profit of 1.028 billion to 1.098 billion yuan for 2025, an increase of 47% to 57% [15] - China Eastern Airlines reported a 4.93% year-on-year increase in passenger capacity for December 2025 [20] Group 5 - *ST Aowei's stock may be delisted due to a closing price below par value [21] - Yilian Network expects a net profit of 2.542 billion to 2.648 billion yuan for 2025, a decrease of 0% to 4% year-on-year [22] - Huochen Co. anticipates a net profit of 420 million to 540 million yuan for 2025, recovering from a loss of 2 million yuan in the previous year [17] Group 6 - Guoli Electronics expects a net profit of 68 million to 80 million yuan for 2025, an increase of 124.89% to 164.57% [28] - Jinchuan Group forecasts a net profit of 11 billion to 12 billion yuan for 2025, a year-on-year increase of 73.57% to 89.34% [41] - Triangle Tire plans to invest 3.219 billion yuan in a new tire project in Cambodia [42]

Core Viewpoint - Jianfeng Group's subsidiary, Jianfeng Pharmaceutical, has voluntarily withdrawn its drug registration clinical trial application for "C2235 and C2235 tablets" due to the need for further documentation improvement [1] Group 1: Company Actions - Jianfeng Pharmaceutical received a termination notice from the National Medical Products Administration regarding the drug registration application [1] - The decision to withdraw the application was made after careful consideration, indicating a proactive approach to ensure compliance and quality [1] Group 2: Future Plans - The company plans to resubmit the drug registration clinical trial application after completing the necessary research improvements [1]

浙江尖峰集团股份有限公司 关于子公司撤回药品注册临床试验申请的公告 证券简称：尖峰集团 证券代码：600668 编号：临 2026-002 1 | | | 二、撤回原因及相关安排 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次浙江尖峰药业有限公司（以下简称"尖峰药业"）收到国家药品监督 管理局签发的关于"C2235 和 C2235 片"《药品注册申请终止通知书》（通知书 编号：2026L05031、2026L05032），系尖峰药业主动撤回申请，待公司完善相关 研究后择期重新提交药品注册临床试验申请。 风险提示：本次尖峰药业申请撤回"C2235 和 C2235 片"药品注册临床 试验申请不会对公司当期业绩产生重大影响。由于创新药研发存在高科技、高风 险的特点，前期研发以及产品从研制、临床试验报批到投产的周期长、环节多， 易受不可预测的因素影响，研发风险不可避免，敬请广大投资者谨慎决策，注意 防范投资风险。 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的全资子公司尖 峰药业收到国家药品监督管理 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Jianfeng Pharmaceutical, has received a termination notice from the National Medical Products Administration regarding the drug registration application for "C2235 and C2235 tablets," which was voluntarily withdrawn by the company to improve related research before resubmitting the clinical trial application [1] Group 1 - Jianfeng Pharmaceutical received a termination notice for the drug registration application for "C2235 and C2235 tablets" [1] - The withdrawal of the application is a proactive measure by the company to enhance its research [1] - The withdrawal of the clinical trial application will not have a significant impact on the company's current performance [1]